Review Article
Volume 10 Issue 8 - 2021
Several Vaccinations are Available for the Prevention of the SARS-CoV-19 Virus and its Overall Utility in Males and Women of Reproductive Age
Bezar Ghan VV*, Vineeth Reddy Lekkala, Geetha Reddy, Ram Reddy and Raja Gopal K
Amrutha Fertility Centre, Yenapoya Medical College, Yenapoya University, India
*Corresponding Author: Bezar Ghan VV, Amrutha Fertility Centre, Yenapoya Medical College, Yenapoya University, India.
Received: June 17, 2021; Published: July 19, 2021


Ever since Covid-19 was marked as a global pandemic and health concern, there have been many attempts to prevent the disease from spreading. Countries all around the world are using different biotechnological techniques to mass produce and manufacture safe and efficient vaccines. Currently available in the market to immunize people against the deadly corona-virus are messenger RNA, viral vectors and live attenuated vaccines, commonly known under their brand names of Pfizer, BioNTech, Oxford AstraZeneca, and Sputnik V, amongst others that are available. Though it is known that these vaccines provide sufficient efficacy against the virus, there isn’t sufficient documentation regarding the effect of these covid-19 vaccines on child bearing. In the creation of every vaccine, there is a set of procedures that must be followed. The exploratory stage comes first following vaccine design, followed by pre-clinical trials. Once the safety of the drug has been shown in animal models, it is tested in people in three stages: phase 1, phase 2 and phase 3. After that, it goes through a rigorous examination to evaluate its efficacy before being approved for mass manufacturing. This is a lengthy procedure that takes anywhere from 10 to 15 years to complete. These phases have been shortened in the development of a vaccine for Covid-19, and vaccinations have already been given to the general public. The long term effects of the vaccine is not known and it is not yet elucidated whether these vaccines have an impact on overall fertility in men and women of reproductive ages. Our review article discusses the various vaccines present for Severe Acute Respiratory Syndrome Corona-virus 2 (SARS-CoV-2) and reviews the efficiency of the vaccine in child bearing in both men and women. From our review of different literates, it is evident that the effects of childbearing in men and women that have been vaccinated against corona-virus are poorly understood. This paper acts as a primary guide to encourage future work in this particular area and come to a substantial answer for the same.

Keywords: Covid-19; Vaccines; Fertility; Childbearing Age


  1. Esparza J., et al. “Beyond the myths: Novel findings for old paradigms in the history of the smallpox vaccine”. PLoS Pathogens7 (2018): e1007082.
  2. Shereen MA., et al. “COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses”. Journal of Advanced Research 24 (2020): 91-98.
  3. Fauci AS., et al. “Covid-19—navigating the uncharted (2020).
  4. Sharma O., et al. “A Review of the Progress and Challenges of Developing a Vaccine for COVID-19”. Frontiers in Immunology 11 (2020): 2413.
  5. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet10223 (2020): 497-506.
  6. Cao X. “COVID-19: immunopathology and its implications for therapy”. Nature Reviews Immunology5 (2020): 269-270.
  7. Liu C., et al. “Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases (2002).
  8. Amanat F and Krammer F. “SARS-CoV-2 vaccines: status report”. Immunity4 (2020): 583-589.
  9. Sharma O., et al. “A Review of the Progress and Challenges of Developing a Vaccine for COVID-19”. Frontiers in Immunology 11 (2020): 2413.
  10. Shahcheraghi SH., et al. “An overview of vaccine development for COVID-19”. Therapeutic Delivery3 (2021): 235-244.
  11. Caddy S. Developing a vaccine for covid-19 (2020).
  12. Wang H., et al. “Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2”. Cell3 (2020): 713-721.
  13. Xia S., et al. “Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial”. The Lancet Infectious Diseases1 (2021): 39-51.
  14. Clem AS. “Fundamentals of vaccine immunology”. Journal of Global Infectious Diseases1 (2020): 73.
  15. Syomin BV and Ilyin YV. “Virus-like particles as an instrument of vaccine production”. Molecular Biology3 (2019): 323-334.
  16. Mukherjee R. “Global efforts on vaccines for COVID-19: Since, sooner or later, we all will catch the coronavirus”. Journal of Biosciences 45 (2020): 1-10.
  17. Walls AC., et al. “Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein”. Cell2 (2020): 281-292.
  18. Tai W., et al. “. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine”. Cellular and Molecular Immunology6 (2020): 613-620.
  19. Wang F., et al. “An evidence based perspective on mRNA-SARS-CoV-2 vaccine development”. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 26 (2020): e924700-924701.
  20. Smith TR., et al. “Immunogenicity of a DNA vaccine candidate for COVID-19”. Nature Communications 1 (2020): 1-13.
  21. Choi Y and Chang J. “Viral vectors for vaccine applications”. Clinical and Experimental Vaccine Research 2 (2013): 97.
  22. Kim MH., et al. “Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus”. PLoS One7 (2019): e0220196.
  23. Bhagavathula AS., et al. “Vaccines and drug therapeutics to lock down novel coronavirus disease 2019 (COVID-19): a systematic review of clinical trials”. Cureus5 (2020).
  24. Graham RL., et al. “A decade after SARS: strategies for controlling emerging coronaviruses”. Nature Reviews Microbiology12 (2013): 836-848.
  25. Zhang L and Liu Y. “Potential interventions for novel coronavirus in China: A systematic review”. Journal of Medical Virology5 (2020): 479-490.
  26. Livingston EH. “Necessity of 2 doses of the Pfizer and Moderna COVID-19 vaccines”. The Journal of the American Medical Association9 (2021): 898-898.
  27. Mahase E. “Covid-19: UK approves Moderna vaccine to be given as two doses 28 days apart (2021).
  28. Meo SA., et al. “COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines”. European Review for Medical and Pharmacological Sciences 3 (2021): 1663-1669.
  29. Sadoff J., et al. “Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19”. New England Journal of Medicine (2021).
  30. Mahase E. “Covid-19: US suspends Johnson and Johnson vaccine rollout over blood clots (2021).
  31. Knoll MD and Wonodi C. “Oxford–AstraZeneca COVID-19 vaccine efficacy”. The Lancet10269 (2021): 72-74.
  32. Mallapaty S and Callaway E. “What scientists do and don’t know about the Oxford-AstraZeneca COVID vaccine”. Nature7852 (2021): 15-17.
  33. Mahase E. “How the Oxford-AstraZeneca covid-19 vaccine was made”. British Medical Journal (2021): 372.
  34. Wise J. “Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing interval (2021).
  35. Wise J. “Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots (2021).
  36. Baraniuk C. “Covid-19: What do we know about Sputnik V and other Russian vaccines?” British Medical Journal (2021): 372.
  37. Logunov DY., et al. “Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia”. The Lancet10275 (2021): 671-681.
  38. Dobrovidova O. “Latest Russian vaccine comes with a big dose of mystery (2021).
  39. Ella R., et al. “Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial”. The Lancet Infectious Diseases5 (2021): 637-646.
  40. Thiagarajan K. “What do we know about India’s Covaxin vaccine?” British Medical Journal (2021): 373.
  41. Singh AK., et al. “Antibody Response after First-dose of ChAdOx1-nCOV (Covishield) and BBV-152 (Covaxin) amongst Health Care Workers in India: Preliminary Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study”. Med Rxiv (2021).
  42. Mallapaty S. “China COVID vaccine reports mixed results—what does that mean for the pandemic?” Nature (2021): 15.
  43. Phase III. Sinovac COVID-19 vaccine, CoronaVac.
  44. Nami S., et al. “Fungal vaccines, mechanism of actions and immunology: a comprehensive review”. Biomedicine and Pharmacotherapy 109 (2019): 333-344.
  45. Dyer O. “Covid-19: India sees record deaths as “black fungus”. Spreads Fear (2021).
  46. Liu M., et al. “Saccharomyces as a vaccine against systemic candidiasis”. Immunological Investigations8 (2012): 847-855.
  47. Liu M., et al. “Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection”. Vaccine9 (2011): 1745-1753.
  48. Karch CP and Burkhard P. “Vaccine technologies: from whole organisms to rationally designed protein assemblies”. Biochemical Pharmacology 120 (2016): 1-14.
  49. Devi SJ. “Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model”. Vaccine9 (1996): 841-844.
  50. Santos E and Levitz SM. “Fungal vaccines and immunotherapeutics”. Cold Spring Harbor Perspectives in Medicine11 (2014): a019711.
  51. Span P. “Older adults may be left out of some COVID-19 trials”. The New York Times (2020).
Citation: Bezar Ghan VV., et al. “Several Vaccinations are Available for the Prevention of the SARS-CoV-19 Virus and its Overall Utility in Males and Women of Reproductive Age”. EC Gynaecology 10.8 (2020): 01-12.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

November Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 09, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.